Traffic Jams II: An update of diseases of intracellular transport

Traffic

Volumn 3, Issue 11, 2002, Pages 781-790

  Aridor, Meir ^a   Hannan, Lisa A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b TSRI IMM34   (United States)

Author keywords

Disease; Syndrome; Traffic; Transport

Indexed keywords

APOLIPOPROTEIN B48; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CAVEOLIN 3; CERULOPLASMIN; CONNEXIN 32; CYSTATHIONINE BETA SYNTHASE; GELSOLIN; GLUCOSAMINIDASE; INITIATION FACTOR 2; MULTIDRUG RESISTANCE PROTEIN 2; N ACETYLGALACTOSAMINE 4 SULFATASE; NEPHRIN; PALMITOYL PROTEIN THIOESTERASE; PARKIN; PENDRIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLYGLUTAMINE; RAB PROTEIN; RHODOPSIN; SODIUM CHANNEL; SULFONYLUREA RECEPTOR; CARRIER PROTEIN;

ALPHA CHAIN; ARTICLE; ASPARTYLGLYCOSAMINURIA; AUTOIMMUNE DISEASE; BLINDNESS; BLOOD DISEASE; BONE DYSPLASIA; BRUGADA SYNDROME; CARCINOGENESIS; CELL FATE; CELL FUNCTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIABETES MELLITUS; DUBIN JOHNSON SYNDROME; ENDOPLASMIC RETICULUM; GENE MUTATION; HEART DISEASE; HOMEOSTASIS; HUMAN; INTRACELLULAR TRANSPORT; KIDNEY DISEASE; MUSCLE DISEASE; PATHOPHYSIOLOGY; PENDRED SYNDROME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN TRANSPORT; QUALITY CONTROL; REGULATORY MECHANISM; VASCULAR DISEASE; GENERAL ASPECTS OF DISEASE; GENETICS; GLYCOSYLATION; METABOLISM; MUTATION; NOTE; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CARRIER PROTEINS; DISEASE; ENDOPLASMIC RETICULUM; GLYCOSYLATION; HUMANS; MUTATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 0036843129     PISSN: 13989219     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0854.2002.31103.x     Document Type: Article

References (63)

1. Baroudi G, Pouliot V, Denjoy I, Guicheney P, Shrier A, Chahine M. Novel mechanism for Brugada syndrome. defective surface localization of an SCN5A mutant (R1432G). Circ Res 2001;88:E78-83.
2. Baroudi G, Acharfi S, Larouche C, Chahine M. Expression and intracellular localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada syndrome. Circ Res 2002;90:E11-E16.
3. Liu L, Done SC, Khoshnoodi J, Bertorello A, Wartiovaara J, Berggren PO, Tryggvason K. Defective nephrin trafficking caused by missense mutations in the NPHS1 gene: insight into the mechanisms of congenital nephrotic syndrome. Hum Mol Genet 2001;10:2637-2644.
4. Mor-Cohen R, Zivelin A, Rosenberg N, Shani M, Muallem S, Seligsohn U. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001;276:36923-36930.
5. Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, Keppler D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 2000;32:1317-1328.
6. Tsujii H, Konig J, Rost D, Stockel B, Leuschner U, Keppler D. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 1999;117:653-660.
7. Kartenbeck J, Leuschner U, Mayer R, Keppler D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996;23:1061-1066.
8. Sabbagh Y, Boileau G, DesGroseillers L, Tenenhouse HS. Disease-causing missense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Hum Mol Genet 2001; 10:1539-1546.
9. Taylor J P, Metcalfe RA, Watson PF, Weetman AP, Trembath RC. Mutations of the PDS gene, encoding pendrin, are associated with protein mislocalization and loss of iodide efflux: implications for thyroid dysfunction in Pendred syndrome. J Clin Endocrinol Metab 2002;87: 1778-1784.
10. Taschenberger G, Mougey A, Shen S, Lester LB, LaFranchi S, Shyng SL. Identification of a familial hyperinsulinism-causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of KATP channels. J Biol Chem 2002;277:17139-17146.
11. Quilty JA, Reithmeier RA. Trafficking and folding defects in hereditary spherocytosis mutants of the human red cell anion exchanger. Traffic 2000;1:987-998.
12. Hellman NE, Kono S, Miyajima H, Gitlin JD. Biochemical analysis of a missense mutation in aceruloplasminemia. J Biol Chem 2002;277: 1375-1380.
13. Salonen T, Heinonen-Kopra O, Vesa J, Jalanko A. Neuronal trafficking of palmitoyl protein thioesterase provides an excellent model to study the effects of different mutations which cause infantile neuronal ceroid lipofuscinocis. Mol Cell Neurosci 2001;18:131-140.
14. Kleerekoper Q, Hecht JT, Putkey JA, Disease-causing mutations in cartilage oligomeric matrix protein cause an unstructured Ca2+ binding domain. J Biol Chem 2002;277:10581-10589.
15. Maddox BK, Keene DR, Sakai LY, Charbonneau NL, Morris NP, Ridgway CC, Boswell BA, Sussman MD, Horton WA, Bachinger HP, Hecht JT. The fate of cartilage oligomeric matrix protein is determined by the cell type in the case of a novel mutation in pseudoachondroplasia. J Biol Chem 1997;272:30993-30997.
16. Edwards AO, Donoso LA, Ritter R, 3rd. A novel gene for autosomal dominant Stargardt-like macular dystrophy with homology to the SUR4 protein family. Invest Ophthalmol Vis Sci 2001;42:2652-2663.
17. Saarela J, Laine M, Oinonen C, Schantz C, Jalanko A, Rouvinen J, Peltonen L. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations. Hum Mol Genet 2001;10:983-995.
18. VanSlyke JK, Deschenes SM, Musil LS. Intracellular transport, assembly, and degradation of wild-type and disease-linked mutant gap junction proteins. Mol Biol Cell 2000;11:1933-1946.
19. Kaushal S, Khorana HG. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa. Biochemistry 1994;33:6121-6128.
20. Sung CH, Schneider BG, Agarwal N, Papermaster DS, Nathans J. Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci USA 1991;88:8840-8844.
21. Sung CH, Davenport CM, Nathans J. Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain. J Biol Chem 1993; 268:26645-26649.
22. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000;25:406-409.
23. Harding HF, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD, Ron D. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell 2001;7:1153-1163.
24. Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P. Saunders T, Bonner-Weir S, Kaufman RJ. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 2001;7:1165-1176.
25. Sai X, Kawamura Y, Kokame K, Yamaguchi H, Shiraishi H, Suzuki R, Suzuki T, Kawaichi M, Miyata T, Kitamura T, De Strooper B, Yanagisawa K, Komano H. Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein. J Biol Chem 2002;277:12915-12920.
26. Imai Y, Soda M, Hatakeyama S, Akagi T, Hashikawa T, Nakayama KI, Takahashi R. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell 2002;10:55-67.
27. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001;105:891-902.
28. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 2000;275:35661-35664.
29. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A. Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;293:263-269.
30. Mbikay M, Seidah NG, Chretien M. Neuroendocrine secratory protein 7B2: structure, expression and functions. Biochem J 2001;357:329-342.
31. Bassi MT, Manzoni M, Monti E, Pizzo MT, Ballabio A, Borsani G. Cloning of the gene encoding a novel integral membrane protein, mucolipidin and identification of the two major founder mutations causing mucolipidosis type IV. Am J Human Genet 2000;67:1110-1120.
32. Partridge CJ, Beech DJ, Sivaprasadarao A. Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism. J Biol Chem 2001;276:35947-35952.
33. Galbiati F. Volonte D, Minetti C, Chu JB, Lisenti MP. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the Golgi complex. J Biol Chem 1999;274:25632-25641.
34. Galbiati F, Volonte D, Minetti C, Bregman DB, Lisanti MP. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutant and rescues wild-type caveolin-3. J Biol Chem 2000;275: 37702-37711.
35. Bradford TM, Litjens T, Parkinson EJ, Hopwood JJ, Brooks DA. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine 4-sulfatase at multiple points in the vacuolar network. Biochemistry 2002;41:4962-4971.
36. Chen CD, Huff ME, Matteson J, Page L, Phillips R, Kelly JW, Balch WE. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca (2+) stabilization. EMBO J 2001;20:6277-6287.
37. Berriot-Varoqueaux N, Dannoura AH, Moreau A, Verthier N, Sassolas A, Cadiot G, Lachaux A, Munck A, Schmitz J, Aggerbeck LP, Samson-Bouma ME. Apolipoprotein B48 glycosylation in abetalipoproteinemia and Anderson's disease. Gastroenterology 2001;121:1101-1108.
38. Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, Takeda S, Yang HW, Terada S, Nakata T, Takei Y, Saito M, Tsuji S, Hayashi Y, Hirokawa N. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. [erratum appears in Cell 2001, July 13;106 (1): 127.] Cell 2001;105:587-597.
39. Litovchick L, Marshak E, Shaltiel S. A selective interaction between OS-9 and the carboxyl-terminus tail of meprin beta. J Biol Chem 2002;277:34413-34433.
40. Friedmann E, Salzberg Y, Weinberger A. Shaltiel S, Gerst JE. YOS9, the putative yeast homolog of a gene amplified in osteosarcomas, is involved in the ER-Golgi transport of GPI-anchored proteins. J Biol Chem 2002; in press.
41. Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, Dunbar CE. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 2001;98:2518-2525.
42. Wu G, Yussman MG, Barrett TJ, Hahn HS, Osinska H, Hilliard GM, Wang X, Toyokawa T, Yatani A, Lynch RA, Robbins J, Dorn GW, 2nd. Increased myocardial Rab GTPase expression. a consequence and cause of cardiomyopathy. Circ Res 2001;89:1130-1137.
43. Estrada L, Caron E, Gorski JL. Fgd1, the Cdc42 guanine nucleotide exchange factor responsible for faciogenital dysplasia, is localized to the subcortical actin cytoskeleton and Golgi membrane. Hum Mol Genet 2001;10:485-495.
44. Hewett J, Gonzalez-Agosti C, Slater D, Ziefer P, Li S, Bergeron D, Jacoby DJ, Ozelius LJ, Ramesh V, Breakefield XO. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Hum Mol Genet 2000;9:1403-1413.
45. Nishitoh H, Matsuzawa A, Tobiume K, Saegusa K, Takeda K, Inoue K, Hori S, Kakizuka A, Ichijo H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 2002;16:1345-1355.
46. Zhang C, Kawauchi J, Adachi MT, Hashimoto Y, Oshiro S, Aso T, Kitajima S. Activation of JNK and transcriptional repressor ATF3/LRF1 through the IRE1/TRAF2 pathway is implicated in human vascular endothelial cell death by homocysteine. Biochem Biophys Res Commun 2001;289:718-724.
47. Zhang C. Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, Kitajima S. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 2001;276:35867-35874.
48. Selak S, Chan EK, Schoenroth L, Senecal JL, Fritzler MJ. Early endosome antigen. 1: an autoantigen associated with neurological diseases. J Invest Med 1999;47:311-318.
49. Matthijs G, Schollen E, Pardon E, Velga-Da-Cunha M, Jaeken J. Cassiman JJ, Van Schaftingen E. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat Genet 1997;16:88-92.
50. Jaeken J, Matthijs G. Congenital disorders of glycosylation. Annu Rev Genomics Hum Genet 2001;2:129-151.
51. Aebi M, Hennet T. Congenital disorders of glycosylation: genetic model systems lead the way. Trends Cell Biol 2001;11:136-141.
52. Niehues R, Hasilik M, Alton G, Korner C, Schiebe-Sukumar M, Koch HG, Zimmer KP, Wu R, Harms E, Reiter K, von Figura K, Freeze HH, Harms HK, Marquardt T. Carbohydrate-deficient glycoprotein syndrome type lb. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest 1998;101:1414-1420.
53. Burda P, Borsig L, de Rijk-van Andel J, Wevers R, Jaeken J, Carchon H, Berger EG, Aebi M. A novel carbohydrate-deficient glycoprotein syndrome characterized by a deficiency in glucosylation of the dolichol-linked oligosaccharide. J Clin Invest 1998;102:647-652.
54. Imbach T, Burda P, Kuhnert P, Wevers RA, Aebi M, Berger EG, Hennet T. A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-lc. Proc Natl Acad Sci USA 1999;96:6982-6987.
55. Korner C, Knauer R, Stephani U, Marquardt T, Lehle L, von Figura K. Carbohydrate deficient glycoprotein syndrome type IV: deficiency of dolichyl-P-Man:Man(5) GlcNAc(2)-PP-dolichyl mannosyltransferase. EMBO J 1999;18:6816-6822.
56. Kim S, Westphal V, Srikrishna G, Mehta DP, Peterson S, Filiano J, Karnes PS, Patterson MC, Freeze HH. Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation le (CDG-le). J Clin Invest 2000;105:191-198.
57. Imbach T, Schenk B, Schollen E, Burda P, Stutz A, GrJunewald S, Bailie NM, King MD, Jaeken J, Matthijs G, Berger EG, Aebi M, Hennet T. Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type le. J Clin Invest 2000;105:233-239.
58. Schenk B, Imbach T, Frank CG, Grubenmann CE, Raymond GV, Hurvitz H, Raas-Rotschild A, Luder AS, Jaeken J, Berger EG, Matthijs G, Hennet T, Aebi M. MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If. J Clin Invest 2001;108: 1687-1695.
59. De Praeter CM, Gerwig GJ, Bause E, Nuytinck LK, Vliegenthart JF, Breuer W, Kamerling JP, Espeel MF, Martin JJ, De Paepe AM, Chan NW, Dacremont GA, Van Coster RN. A novel disorder caused by defective biosynthesis of N-linked oligosaccharides due to glucosidase I deficiency. Am J Hum Genet 2000;66:1744-1756.
60. Lubke T, Marquardt T, von Figura K, Korner C. A new type of carbohydrate-deficient glycoprotein syndrome due to a decreased import of GDP-fucose into the Golgi. J Biol Chem 1999;274:25986-25989.
61. Hansske B, Thiel C, Lubke T, Hasilik M, Honing S, Peters V, Heidemann PH, Hoffmann GF, Berger EG, von Figura K, Korner C. Deficiency of UDP-galactose: N-acetylglucosamine beta-1,4-galactosyltransferase I causes the congenital disorder of glycosylation type lld. J Clin Invest 2002;109:725-733.
62. Quentin E, Gladen A, Roden L, Kresse H. A genetic defect in the biosynthesis of dermatan sulfate proteoglycan: galactosyltransferase I deficiency in fibroblasts from a patient with a progeroid syndrome. Proc Natl Acad Sci USA 1990;87:1342-1346.
63. McCormick C, Duncan G, Goutsos KT, Tufaro F. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci USA 2000;97:668-673.